- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03127605
Inotuzumab Ozogamicin - PF-05208773
May 14, 2020 updated by: Pfizer
Inotuzumab Ozogamicin Expanded Access Program
Study Overview
Status
Approved for marketing
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 20, 2017
First Submitted That Met QC Criteria
April 24, 2017
First Posted (Actual)
April 25, 2017
Study Record Updates
Last Update Posted (Actual)
May 18, 2020
Last Update Submitted That Met QC Criteria
May 14, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B193
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inotuzumab Ozogamicin
-
PfizerUCB PharmaCompletedLymphomaUnited States, Belgium, Japan, Korea, Republic of, Germany, Hong Kong, Hungary, Netherlands, Singapore
-
Nicola GoekbugetRecruitingPrecursor Cell Lymphoblastic LeukemiaGermany
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Lymphoid LeukemiaItaly
-
PfizerCompletedLymphoma, B-CellUnited States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
-
Novartis PharmaceuticalsWithdrawn
-
Institute of Hematology & Blood Diseases HospitalNot yet recruiting
-
PfizerCompletedLeukemia | Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | ACUTE LYMPHOBLASTIC LEUKEMIAUnited States, Spain, Taiwan, Singapore, India, Hungary, Turkey, Poland
-
PfizerActive, not recruiting
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingMinimal Residual Disease | Bone Marrow Transplant | Ph+ ALLChina